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esponsibility of InstAbstract Ikaros represents a zinc-ﬁnger protein family important for lymphocyte development and
certain other physiological processes. The number of family members is large, with alternative splicing
producing various additional isoforms from each of the ﬁve homologous genes in the family. The
functional forms of Ikaros proteins could be even more diverse due to protein–protein interactions readily
established between family members. Emerging evidence suggests that targeting Ikaros proteins is feasible
and effective in therapeutic applications, although the exact roles of Ikaros proteins remain elusive within
the intricate regulatory networks in which they are involved. In this review we collect existing knowledge
as to the functions, regulatory pathways, and molecular mechanisms of this family of proteins in an
attempt to gain a better understanding through the comparison of activities and interactions among family
members.
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Ikaros was ﬁrst identiﬁed in 19921, where it displayed a strong
phenotype in lymphocyte development. After over two decades of
research, the situation became increasingly complex; four homo-
logs were identiﬁed: Helios, Aiolos, Eos, and Pegasus2, and each
gene could produce several protein isoforms through alternative
splicing. Interactions were common among isoforms and across
family members, which presumably could generate a huge number
of complexes through different combinations.
Through dimerization a set of two C2H2 zinc-ﬁngers at the C-
termini mediates protein–protein interactions within the family,
and this highly conserved domain is present in most of the proteins
in the family. Another common feature of the Ikaros proteins is an
N-terminal domain composed of a maximum of four zinc-ﬁnger
motifs for the recognition of target DNA sequences. The number
of N-terminal ﬁngers varies due to alternative splicing, and the
isoforms without these ﬁngers display a dominant negative effect
in transcriptional activation3.
Although their sequences have high similarity, the distribution of
Ikaros family proteins varies. Ikaros, Helios, and Aiolos are mainly
restricted to lymphoid cells and their progenitors at different
developmental stages, despite the absence of Aiolos in hematopoietic
stem cells (HSCs). In addition, Ikaros is also detected in brain, and
both Ikaros and Helios are detected in erythroid cells. Eos and
Pegasus are more widely expressed throughout body, including
skeletal muscle, liver, brain, and heart. The highest Eos expression
level is found in skeletal muscle. The detailed distribution of each
member of Ikaros family is listed in Table 1 2,4-6.
Existing knowledge of the Ikaros family indicates that these
proteins are mainly involved in lymphocyte development, including aTable 1 Distribution of Ikaros family proteins.
Distributiona Ik
Hematopoietic system HSC þ
CLP þ
Pro-T cells þ
DN T cells þ
DP T cells þ
SP T cells þ
Activated T cells þ
Pro-B cells þ
Pre-B cells þ
B cells (mature peripheral) þ
Activated B cells þ
NK þ
Erythroid precursors þ
Myeloid precursors þ
Megakaryocytic cells þ
Non-hematopoietic system Developing nervous system þ
Brain þ
Liver n
Skeletal muscle n
Kidney n
Heart n
CLP, common lymphoid progenitors; DN, double negative; DP, double posi
positive.
n.a.: not available.
aNote: data are not comparable between hematopoietic and non-hematopwide range of processes, such as apoptosis, cell cycle arrest,
proliferation, and differentiation. Accordingly, failure in their proper
regulation leads to various diseases such as cancer and autoimmunity.
More recently, Ikaros and Aiolos were found to be the main
targets for immunomodulatory drug (IMiD)-induced cereblon
(CRBN) ubiquitination and subsequent degradation in the treat-
ment of multiple myeloma patients7. Inhibitors against casein
kinase II (CK2) restored the ability of Ikaros to function as a tumor
suppressor in high-risk leukemia8. Taken together, these ﬁndings
suggest that targeting Ikaros family members was feasible and
highly effective.
To develop different strategies for targeting Ikaros and its
homologs, better understanding of the family is a prerequisite. In
this review, we attempt to summarize the existing knowledge of
the Ikaros family, including their functions, regulatory pathways,
and molecular mechanisms of the regulation. Because there are far
more studies on Ikaros, we discuss it separately from its homologs.2. Ikaros
2.1. Physiological functions
Ikaros was ﬁrst identiﬁed as an important protein for lymphocyte
development from the study of a transgenic mouse model, and
several mice models were generated thereafter to further investi-
gate the function of Ikaros.
Homozygous deletion of exons 4 and 5 (originally called exons
3 and 4 without consideration of the noncoding exon 1) from Ikaros
gene (Ikzf1), which encodes the ﬁrst three N-terminal zinc-ﬁngers,
produced mice lacking T cells, B cells, natural killer (NK) cells, andaros Aiolos Helios Eos Pegasus
– þ n.a. n.a.
þ þ n.a. n.a.
þ þ þ n.a. n.a.
þ þ þ n.a. n.a.
þ þþ þþ n.a. n.a.
þ þþ þ n.a. n.a.
þ þþ þ n.a. n.a.
þ þ þþ n.a. n.a.
þ þþ þ n.a. n.a.
þ þþ þ n.a. n.a.
þ þþþ þ n.a. n.a.
þ þ n.a. n.a.
n.a. þ þ n.a.
n.a. þ þþ þ
n.a. n.a. þþþ þ
n.a. n.a. þ n.a.
n.a. n.a. þ þ
.a. n.a. n.a. þ þ
.a. n.a. n.a. þþ þ
.a. n.a. n.a. þ þ
.a. n.a. n.a. þ þ
tive; HSC, hematopoietic stem cells; NK, natural killer cells; SP: single
oietic systems.
The Ikaros family of zinc-ﬁnger proteins 515their earliest deﬁned progenitors, while the erythroid and myeloid
lineages were intact9. Heterozygous animals also showed enlarged
lymphoid organs and loss of NK cells3.
Deletion of exon 8 led to the inactivation of Ikaros, with loss of
the C-terminal ﬁngers and a bipartite transcription activation
domain. Homozygous mice with this mutation developed defects
in lymphocytes, while fetal T lymphocytes, fetal and adult B
lymphocytes, and their earliest progenitors were absent.
Individual deletion of exon 4 or 6 produced proteins lacking
zinc-ﬁnger 1 or 4, respectively10. The transgenic mice had smaller
amount of conventional B cells compared to wild-type animals.
Mice lacking ﬁnger 1 had substantially decreased numbers of large
pre-BII cells, while mice missing ﬁnger 4 had increased numbers
of these cells. Both kinds of mice displayed fewer small pre-BII
cells, immature B cells, and mature recirculating B cells, while
deletion of ﬁnger 1 showed a more severe phenotype. Upon
deletion of ﬁnger 4, mice displayed reduced CD4–CD8– double-
negative (DN) thymocytes, in contrast to a relatively normal
number of DN population in the ﬁnger1-mutant mice. Detailed
analysis suggested that the aberrant Ikaros led to a reduction of
dynamic ranges of down-stream gene expression changes during
thymocyte developmental transitions11.
Conditional deletion of Ikzf1 exon 5 in mice12, which eliminates
ﬁngers 2 and 3 at the N-terminus, arrested pre-B cell differentia-
tion at a stage with augmented proliferation and self-renewal
signaling [mitogen-activated protein kinase (MAPK) pathway] and
attenuated differentiation signaling (pre-B cell receptor pathway,
preBCR pathway).
Apart from the exon deletion mutants, a knock-in mouse strain
with a β-galactosidase in-frame insertion in Ikzf1 exon 2 displayed
reduced Ikaros function compared to the wild-type13. Fetal B cells
were absent in the homozygous animals, but B cells nevertheless
developed postnatally from a reduced pool of precursors.
Consistent with the results from mouse models displaying
lymphocyte defects in development upon Ikaros mutation, clinical
studies found genetic alterations in Ikaros strongly correlated to a
poor outcome in high-risk acute lymphoblastic leukemia (ALL)
patients. In Philadelphia chromosome-carrying ALL (BCR-ABL1
ALL) patients, 83.7% patients had alterations in IKZF1, which
resulted in haplo-insufﬁciency, expression of dominate negative
isoform of Ikaros, or complete loss of Ikaros expression14.Figure 1 The regulatioRecombination activating gene (RAG) was thought to be respon-
sible for the deletion mutation of Ikaros in BCR-ABL1 ALL
patients. In another study which addressed young ALL patients
without the Philadelphia chromosome, alteration in IKZF1 was
also found to be strongly associated with a poor clinic outcome15.2.2. Regulatory pathways
While phenotypes are most signiﬁcant in lymphocyte differentia-
tion, studies on signaling pathways in this area have attracted some
attention. The preBCR signaling pathway has been extensively
studied and produced a relatively clear picture of the regulatory
network (Fig. 1). Upon preBCR activation, the coreceptors Igα/Igβ
were phosphorylated by LYN, a SRC family protein-tyrosine
kinase, followed by the recruitment and activation of spleen
tyrosine kinase (SYK), which phosphorylated CD19 and B-cell
phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) adaptor
protein (BCAP). PI3K was consequently recruited to the cell
membrane through the binding to CD19 and BCAP, and catalyzed
the conversion of phosphatidylinositol (4,5) diphosphate [PI(4,5)
P2] into phosphatidylinositol (3,4,5) triphosphate (PIP3), which
was a favorite binding site for PH domain-containing signaling
proteins such as protein kinase AKT, Bruton's tyrosine kinase
(BTK) and phospholipase Cγ2 (PLCγ2). Membrane-bound AKT
was activated through phosphorylation at T308 and S473, and
subsequently translocated into the nucleus to phosphorylate
transcription factor FOXO1, which was in turn exported out of
nucleus and subjected to proteasome degradation. The decreased
expression level of FOXO1 led to improper splicing of Ikaros
mRNA16.
While an activated preBCR pathway eventually reduces Ikaros
activity, Ikaros counteracted the effect by projecting suppressions
at two sites of the pathway. First, Ikaros repressed expression of
the Igll1 gene which encodes preBCR component λ51. Over-
expression of Ikaros consistently led to reduction in the phosphor-
ylation of SLP65, which was a substrate of SYK downstream of
preBCR. SLP65 (also known as BLNK), activated by SYK
phosphorylation, was a crucial protein for B-cell activation, which
promoted apoptosis through the interaction with PLCγ217 and
arrested the cell cycle through the inhibition of the JAK3/STAT5n network of Ikaros.
Yingzhi Fan, Duo Lu516pathway18. Secondly, the activity of the SRC kinase LYN was also
inhibited by Ikaros, and subsequently restrained the abilities of E3
ligase CBL to ubiquitinylate SYK for proteasomal degradation and
to interact with SLP65 by competing with PLCγ219. Thus, Ikaros
up-regulated SYK expression through the LYN/CBL pathway, but
down-regulated SYK phosphorylation through the preBCR path-
way. It is worth mentioning that SLP65 was suggested to inhibit
the phosphorylation of AKT at S473 and promote FOXO1
stability20. This putatively should promote Ikaros activity,
although existing data suggests that Ikaros mRNA level was not
affected upon SLP65 reconstitution in SLP65-deﬁcient pre-B
cells21.
Surprisingly, Ikaros was shown to down-regulate the expression
of the inositol 5-phosphatase SHIP, which dephosphorylated the
membrane component PIP3 at position 5 of the inositol ring. The
modiﬁcation on the membrane blocked the recruitment and
subsequent activation of AKT, BTK and PLCγ2. Hence, Ikaros
appeared to support AKT activation by downregulating SHIP,
while Helios displayed the opposite function22. Collectively, an
intricate network was built between Ikaros and preBCR, which
included major nodes of LYN, CBL, SYK, SLP65, PI3K, SHIP,
AKT and FOXO1.
Another relatively well-studied Ikaros-related pathway is the
Notch pathway, which is important for tumor cell proliferation. A
study of T-cell leukemogenesis demonstrated that in a pre-T cell
receptor (preTCR)-dependent mode, Notch3 elevated the expres-
sion of the RNA binding protein HuD, which shifted the
alternative splicing pattern of Ikaros towards the dominate-
negative isoform23. Reciprocally, by competing with CSL (also
known as RBP-Jk) at DNA binding sites in promoter regions,
Ikaros counteracted the Notch effect on CSL activation and
repressed the expression of downstream genes including the
component of preTCR pre-Tα24.
A recent study suggested that Ikaros was a target of the MAPK
signaling pathway25: ERK1/2-mediated phosphorylation of ETS1
repressed its ability to up-regulate the expression of Ikaros. On the
other hand, in the Ikzf1 exon 5–deleted mice, elevated activity of
ERK1/2 was observed, which correlated with a faster transit
through the cell-cycle in large pre-B cells12. The augmented
ERK1/2 activity was thought a result of the activated signaling
pathway for integrin which was normally repressed by Ikaros in
wild-type animals.
Ikaros was under the inﬂuence of several interferon regulatory
factors (IRFs), which were important for B cell development and
the inﬂammatory response of the immune system. Early study on
pre-B cell development showed that IRF4 and 8 induced the
expression of Ikaros and its homolog Aiolos, which worked
together to inhibit preBCR expression and led to the cell-cycle
withdrawal of small pre-B cells26. However, a more recent study
on the B cell IgG2a/c isotype class-switch suggested that IRF8 but
not IRF4 activated the IKZF1 promoter, and IRF5 could inhibit
such activation27.
Post-translation modiﬁcations were detected on Ikaros. CK2
kinase was found to phosphorylate Ikaros at several sites and
consequently lower it DNA afﬁnity, while Protein Phosphatase 1
(PP1) had the ability to remove such modiﬁcation8. SYK was also
found to phosphorylate Ikaros but at different sites, which affected
the nuclear localization of Ikaros28. Small ubiquitin-like modiﬁer
(SUMO)-ylation was detected on Ikaros29, which disrupted Ikaros
interactions with transcriptional corepressors such as Sin3A,
Sin3B, Mi-2β and CtBP, and impaired the repressive activity of
Ikaros. In this case, the nuclear localization of Ikaros was notaffected. The process of SUMOylation was actively regulated by
SUMO isopeptidases Senp1 and Axam and E3 ligases PIASx and
PIAS3. Likewise, under the induction of IMiDs, Ikaros was
ubiquitinylated by E3 ligase CRBN7 and was subsequently
degraded by proteasomes.
While Ikaros was targeted by many regulatory pathways, this
transcription factor was shown to affect a large number of
downstream proteins. Genome-wide analysis discovered thousands
of DNA binding-sites for Ikaros30, and many sites had been
reported in individual studies. Unsurprisingly, many downstream
genes were important for lymphocyte development, such as dntt31
(encoding TdT) and RAG locus32 for VDJ recombination, CD8α
locus33, CD3δ, IL234, Ahr, Runx135 and STAT436 for T cell
differentiation, IGF-IR in T cell lymphoma37, and cMyc in B cell
differentiation38, apart from those already mentioned above. In
addition to lymphonoid genes, many hematopoietic genes, genes
from the neuroendocrine system, and certain cancer markers were
regulated by Ikaros, such as surface marker CD133 of cancer stem
cells25, LDL-R and POMC in pituitary cells39, iNOS in macro-
phages40, γ-globin41 and GATA1 in primary megakaryocytes42,
while GATA1 was also found to repress Ikaros expression.2.3. Molecular mechanisms
Ikaros functions through transcriptional regulation of its down-
stream proteins. Several levels of Ikaros-mediated transcriptional
regulation have been proposed.
At the chromosome level, Ikaros was detected at discrete
heterochromatin-containing foci in interphase nuclei, in complex
with another family member, Helios43, and transcriptionally
inactive genes localized with centromeric Ikaros complexes in B
cell nuclei44. This led to the suggestion that the transcription
activity was compartmentalized, and Ikaros performed as a
recruiter to bring target genes to a speciﬁc region. Further detailed
analysis suggested that the DNA binding feature of Ikaros was
closely correlated to the pericentromeric localization, and repla-
cing the C-terminal zinc-ﬁnger region with a leucine-zipper
dimerization motif did not appear to affect the formation of
heterochromatin targeting45.
At the nucleosomal level, Ikaros was found to associate with the
nucleosome-remodeling and histone deacetylase (NuRD) complex
to repress downstream genes46. The interaction between Ikaros and
NuRD has been probed, and while the NuRD core element Mi-2β
was thought to associate with the N- and C-terminal zinc-ﬁnger
regions of Ikaros, another component of NuRD, HDAC2 was
mapped onto a much wider region covering the previous two
parts47. Another remodeling complex SWI/SNF was also detected
in association with Ikaros, which was generally considered an
activator for downstream genes. A weak but speciﬁc interaction
was noticed between Ikaros and Brg-1 SWI/SNF ATPase48.
At the RNA polymerase II (PolII) level, Ikaros regulated
transcription initiation in association with C-terminal binding
protein (CtBP) and CtBP-interacting protein (CtIP), which
repressed transcription initiation through the interactions with
general transcription factors TFIIB and TBP in the transcription
pre-initiation complex. For example, Ikaros interacted with,
retinoblastoma protein (Rb), CtBP and CtIP to repress the
promoter of thymidine kinase49, and the interaction between
Ikaros and CtBP was also detected in the repression of CD133
expression25. A PEDLS sequence motif at Ikaros N-terminus was
thought important for the interaction of CtBP5.
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elongation. By interacting with both CDK9 and PP1, Ikaros was
proposed to transfer CDK9 to PP1α for dephosphorylation50.
Consequently CDK9-containing positive transcription elongation
factor b (P-TEFb) was prone to the dissociation from the inactive
7SK complex. The released P-TEFb gained access to PolII through
association with gene regulatory region, where CDK9 phosphory-
lated the C-terminal domain (CTD) of PolII and transcription
pausing factors NELF and DSIF and released PolII from the
pausing phase into transcription elongation. Thus, through PP1/
CDK9/CTD/NELF/DSIP, Ikaros promoted transcription elonga-
tion of PolII.
Ikaros was proposed to mediate crosstalk between different
regulatory pathways, considering its simultaneous association with
two functionally different protein machines. At β-globin loci of
adult erythroid cells Ikaros was found in association with both
NuRD (repressor) and SWI/SNF (activator) chromatin remodeling
complexes51. A similar result was also found in proliferating T
cells, while Aiolos was also detected in the NuRD containing
complex48. The presence of two remodeling complexes was
thought to repress γ-globin expression and facilitate the γ- to β-
globin switch. Unfortunately no further investigation was carried
out on the coordination between the two complexes. Similarly both
P-TEFb and NuRD complexes were found in the same complex
with Ikaros in a co-immunoprecipitation (coIP) experiment50,
though NuRD was also found to bind with Ikaros alone. While
the association with the NuRD or NuRD-P-TEFb complex was
Ikaros-dosage dependent, NuRD was thought to perform in the
super complex as a regulatory component for transcription
elongation.Figure 2 The regulation pathways of Aiolos, Helios, and Eos.3. Ikaros homologues
3.1. Aiolos
Within the Ikaros family, Aiolos is most closely related to Ikaros,
which is reﬂected in their similar functions. Aiolos was found to
have a role in the activation of B-cells, maturation of both B-cells
and NK cells52, differentiation of Th17 cells53, and the generation
of high afﬁnity bone marrow plasma cells responsible for long-
term immunity54. Misregulation of Aiolos was correlated to
various diseases. Through the examination of unbiased massively
parallel sequencing of whole exomes (WES), a recurrent mutation
on Aiolos was recently identiﬁed as a putative cancer driver in
chronic lymphocytic leukemia (CLL)55. Up-regulated expression
of Aiolos has been noted in B-cell CLL (B-CLL)56, non-Hodgkin
lymphoma57, lung cancer58, and in peripheral blood mononuclear
cell subsets from systemic lupus erythematosus (SLE) and
rheumatoid arthritis (RA) patients59. In a mouse model, however,
lack of Aiolos expression also led to an SLE-like phenotype60.
Model cell lines used to study Aiolos include Nalm-6 ALL cells,
Jurkat leukemia T-cells, and chicken DT40 lymphoma B-cells61.
Overexpression of Aiolos was found to repress proliferation and
apoptosis in Nalm-6 cells62, but induced apoptosis in Jurkat
cells63. Disruption of Aiolos expression in DT40 cells led to
defects in gene conversion and the cells were prone to apoptosis.
Like Ikaros, Aiolos is under the regulation of the preBCR/
SLP65 pathway. SLP65 reconstitution in SLP65-deﬁcient pre-B
cells led to elevated Aiolos expression21, which was required for
the appropriate silencing of the Igll1 gene in cooperation with
Ikaros during B-cell developmental transition from pre-BI topre-BII stage. In addition, Ikaros, NF-κB, AP4, STAT3, AhR,
and TGFβ were found to promote Aiolos expression53,64,65. IMiD-
induced CRBN ubiquitinylation also targeted Aiolos, in addition to
Ikaros, and led to its degradation. In reverse, a recent study
suggested that Aiolos has the ability to repress the expression of
CRBN component CUL4A, in association with another transcrip-
tion factor Blimp166.
Interplay between Aiolos and cytokines has been widely
studied. IL2 was found to promote tyrosine phosphorylation on
Aiolos, which disrupted the interaction between Aiolos and Ras5.
The released Aiolos stimulated the expression of Bcl-2, and
eventually blocked apoptosis of T cells. IL4 was also found to
promote the phosphorylation of Aiolos, which broke its interaction
with Bcl-XL67. The released Bcl-XL in this case prevented T cell
apoptosis (Fig. 2).In addition to its anti-apoptotic ability, IL2 was thought to
prevent Th17 differentiation, and Aiolos bound to the promoter of
the IL2 gene and repressed its activation53. Another study
demonstrated that Aiolos achieved the down-regulation of IL2
expression in physical association with another transcription
factor, FoxP364. TNFα may repress the expression of Aiolos,
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expression, and the enhanced Aiolos expression was found to
correlate with a higher expression level of the anti-inﬂammation
cytokine IL10 in Th17 cells68. Further study showed that Aiolos
bound to conserved regions of the IL10 locus and promoted
expression of IL1068. The presence of IL10 reinforced the
expression of itself through a yet unknown positive feedback
loop, and IL1β had the ability to block the expression of IL10 in
Th17 cells. Thus, Aiolos promoted Th17 differentiation, which
contributed to inﬂammation, but also promoted the expression of
anti-inﬂammation cytokine IL10 in Th17.
Interestingly, Th17 cells were found to differentiate preferen-
tially from naïve FoxP3þ Tregs in the presence of IL2 and IL1β69,
and the Helios–FoxP3þ subpopulation of Tregs also has IL17 or
IL10 secreting cells70. This subset of Tregs can be isolated ex vivo
based on the differential expression of IL-1RI and CCR7. Aiolos
was expressed in this subset of Tregs, but not the HeliosþFoxP3þ
Treg subset, while Eos displayed an opposite expression pattern.
The Helios–FoxP3þ Tregs are highly suppressive, and IL1β
downregulated their suppressive capacity. Collectively there was
a similarity between Th17 and this subset of Tregs, and it
would be interesting to see whether Aiolos or other members
of the Ikaros family contribute to the functional plasticity of
Th17.
With respect to mechanism, Aiolos was found to disrupt the high-
order chromatin structure that was necessary for long-range enhancer-
promoter interactions of the SHC1 gene, and consequently repressed
the protein expression of a particular isoform of the adapter protein,
p66Shc, and led to anoikis resistance in lung cancer cells58.
3.2. Helios
While early work suggested the involvement of Helios in
leukemia, more recently Helios has been frequently proposed to
function in Treg differentiation. Helios expression was considered
a marker to distinguish thymotic Tregs from peripheral ones71,72.
However, different opinions existed when HeliosþFoxP3þ Tregs
were also detected from the periphery73. In Tregs, expression of
Helios was mostly correlated to the immunosuppressive activity74,
despite the fact that the percentage of HeliosþFoxP3þ Tregs was
found to be increased in active SLE patients75, which was
speculated to reﬂect an unsuccessful attempt to suppress the
autoimmunity. In addition, exhausted CD4þ T cells which arise
during chronic infection were also found to have elevated Helios
expression, but not Treg-marker FoxP376. On the other hand,
enhanced expression of Helios was correlated to the hyper-
responsive NK cells77.
Mouse models were created to investigate the functions of Helios.
By deletion of exon 7 a Helios-null mouse was generated. The animal
developed an RA-like phenotype with time, which was consistent
with its function in Tregs to suppress inﬂammation78. To trace Helios
expression in vivo, a transgenic mouse strain was generated with a
variant green ﬂuorescent protein Venus expressed as the reporter for
Heliosþ cells79. Results from the Helios-reporter mice showed that the
Heliosþ Treg population was superior in ability to suppress both the
antigen-speciﬁc and TCR-stimulated T cell response, and inhibited the
production of cytokines IFN-γ and IL-17.
Little is known about the regulatory pathway of Helios. Several
cell surface proteins could lead to alteration in Helios expression.
NKp46 reduction in NK cells was found to correlate to the
enhanced expression level of Helios77. Antibody engagement of
CD28 on γδ T cell was found to elevate Helios expression80.Ligation of GITR to its antibody correlated with a drastic loss of
Helios and FoxP3, a lower expression level of IL10, and a higher
level of IFN-γ in intratumor Tregs81.
A few exocellular reagents show the ability to affect Helios.
The combination of Vitamin D3 and estradiol was found to induce
VdrþCD4þFoxP3þHeliosþ T regulatory cells from VdrþCD4þ T
cells, and Helios expression was induced due to the action of
calcitriol, the hormone form of Vitamin D382. Cytokine IL2
administration was found to increase the ratio between
FoxP3þHeliosþ Tregs and FoxP3þHelios– Tregs83. TGFβ pro-
moted Helios expression in cooperation with FoxP3, while IL6
inhibited the expression of Helios in murine induced Tregs in a
STAT3-dependent manner84 (Fig. 2). Monocytes expressing IL12
blocked the proliferation of Heliosþ Tregs, while those expressing
TNFα blocked proliferation of Helios– Tregs85.
A detailed study on Helios regulation of downstream genes was
restricted at FoxP3 only. Helios was found to bind to the promoter
region of FoxP3 and promote its expression86. However, a later
study suggested that the effect on FoxP3 was possibly through the
IL-2Rα-STAT5 pathway, in which a lower Helios level suppressed
STAT5 activation, while activated STAT5 was required to
promote expression of FoxP3 by binding to its promoter and
CNS2 enhancer regions78. Enforced expression of STAT5 restored
the expression of FoxP3 in Helios-deﬁcient CD4þ T cells, and
prevented the expression of IFNγ.
3.3. Eos
Eos was ﬁrst identiﬁed in the nervous system4 and was found to
associate with the Nrg-1 intracellular domain to promote the
expression of postsynaptic density protein-95 (PSD-95), a scaf-
folding protein enriched in post-synaptic structures of neural
cells87. Later studies found the involvement of Eos in a wide
range of organic processes, such as cardiac and skeletal muscle
development, osteoclast differentiation and lymphocyte
differentiation.
Eos was found to bind directly to various proteins in the
regulation of downstream genes. Eos associated with MyoD to
regulate the Myh7b/miR-499 gene in cardiac and skeletal muscle88.
The complex of Eos, MITF and PU.1 was found to recruit CtBP
and Sin3A to the promoter sites of Ctsk and Acp5 and to repress
their expression. Once Eos was removed from the promoter sites,
the repression was released, which led to the initiation of
osteoclast differentiation89.
Eos functions in lymphocytes, mostly Treg and Th cells. In
Tregs, Eos was found to interact with FoxP3 directly and induce
chromatin modiﬁcation and consequently downstream gene silen-
cing90. During graft rejection, Eos expression was found to be
reduced in Tregs91. Like Helios, IL6 was able to down-regulate
Eos expression which led to the reprogramming of FoxP3þ Tregs
into helper-like T cells, without altered expression level of
FoxP384,92. The micro RNA miR-17 was found to target Eos
and promote Th17 differentiation93.
An Eos-null transgenic mouse strain was generated by deleting
the last 3 exons, which led to undetectable expression of Eos
mRNA and protein94. The mice nevertheless displayed
normal numbers of Tregs with normal phenotypes which were
fully competent suppressors. On the other hand, the Tconv
cells from these mice had reduced amounts of IL2 secretion after
TCR activation, and the animals developed more severe experi-
mental autoimmune encephalomyelitis as compared to wild-
type mice.
The Ikaros family of zinc-ﬁnger proteins 519Structural studies were performed on Eos, including nuclear
magnetic resonance (NMR) structures of the individual C-terminal
zinc ﬁngers95 and an electron microscopy (EM) study on two C-
terminal ﬁngers of a fusion protein, MBP-tagged Eos96. The NMR
study produced the structure of Eos C-terminal ﬁnger 2 (EosC2),
but failed with EosC1; the homolog protein Pegasus C-terminal
ﬁnger 1 (PegC1) structure was determined instead. Taking PegC1
structure as the reference, a homology model of EosC1 was
generated. Structurally, PegC1 was in a canonical fold for zinc-
ﬁngers, while EosC2 was, surprisingly, in 2 conformations. Based
on the EosC1 model and the structure of EosC2, the surface
electrostatic potential analysis of Eos C-terminal ﬁngers showed a
mixed pattern of charges which was different from nucleic acid-
binding ﬁngers. Through in vitro biochemical assays, the Eos C-
terminal 2-ﬁnger region was found to form a large homo-
multimeric complex, which displayed a sphere shape by electron
microscopy. However, the 3D structure was not pursued in the
EM study.3.4. Pegasus
Little is known on Pegasus. Upon its discovery in the year 2000, it
was shown that Pegasus had the ability to interact with other
homologs in the Ikaros family, and repressed expression of a
reporter gene with its putative recognition element4. In 2011 a
review article revealed an unpublished data where knockdown of
Pegasus in zebra ﬁsh led to subtle effects in many blood cell lines2.
The same group in 2013 reported a study on zebra-ﬁsh suggesting
that Pegasus affected the left-right asymmetry during embryogen-
esis, and the effect was mediated through the transcriptional
regulation of asymmetrical genes pitx2, lefty2, and spaw97.4. Concluding remarks
Ikaros-family proteins have a broad spectrum of functions that
involves intricate signaling pathways and different levels of
regulatory mechanisms. There are clear connections among family
members. For example, Ikaros and Aiolos are both involved in the
pathogenesis of leukemia, and both are targeted by IMiD-induced
degradation. Treg marker FoxP3 is found in regulatory networks
with Aiolos, Helios and Eos, while IL2 is connected to Ikaros,
Aiolos and Helios. Obviously, members of Ikaros family proteins
work together coordinately to conduct particular functions, and the
mechanism behind the coordination is of interest to further
investigations. In addition, while some Ikaros family proteins
have been shown to be targetable by drugs, mainly through the
manipulation of post-translation modiﬁcations at present, informa-
tion on Ikaros proteins at the molecular level will provide more
possibilities to target this biochemically interesting protein family.References
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